University of Colorado Denver
Aurora, Colorado, 80045, United States
NCT Number: NCT01813929
Insulin resistance (IR) is an important contributor to increased cardiovascular disease risk in type 1 diabetes (T1D). The purpose of this study is to measure the effect of metformin on insulin sensitivity, vascular function and compliance, and mitochondrial function in T1D. The long term goal is to identify novel non-glycemic approaches to managing cardiovascular disease risk in T1D. The results of this study may validate a novel approach to T1D treatment that could significantly improve current management of cardiovascular disease risk in this high risk population.
Looking for future studies?
Notify Me25 year–59 year
All sexes
Interventional
Phase 4
Aurora, Colorado, 80045, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Six week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, 500/1000 for one week, and then 1000mg twice daily for the remainder of the 6 week intervention. If uptitration is not tolerated, max dose will be max tolerated dose of at least 500 mg twice daily.
Other names: glucophage
Six-week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, and then the higher dose (850 mg) for the remainder of the 6 week intervention.
Time frame: End of each 6 week intervention period
Determine the effect of metformin on insulin sensitivity in T1D. Reported measure is glucose infusion rate during hyperinsulinemic euglycemic clamp normalized to total body weight. For this measure, insulin was infused at 40 mU/m2 surface area. Blood sugar wass checked every 5 minutes and glucose infusion adjusted to maintain glucose level at 90 mg/dL for 2 hours. The glucose infusion rate for the final 30 minutes is reported as GIR (aka M-value or glucose disposal rate) in mg glucose/kg*min. A higher value corresponds to greater sensitivity to insulin. There is no strictly defined normal range.
Time frame: End of each 6 week intervention period
Measure of endothelial function by brachial ultrasound of the percent dilation after 5 minutes of occlusion.
Time frame: End of each 6 week intervention period
Pulse wave velocity by Sphygmacor as a measure of aortic stiffness in m/sec.
Time frame: End of each 6 week intervention period
Augmentation index by Sphygmacor is a measure of aortic arterial stiffness. AI@75 is the ratio of augmented pressure/pulse pressure adjusted to a heart rate of 75.
Time frame: End of each 6 week intervention period
Oxygen consumption rate with various substrates and max uncoupled O2 consumption.
Measure is performed on permeabilized muscle fibers from biopsy tissue from the vastus lateralis using the Oroboros OxygraphO2k high resolution respirometer. State 3 is full coupled oxygen flux using PMG or PMGS (pyruvate, malate, glutamate, +/- succinate) or OCMS (octanyl carnitine, malate, +/- succinate) as substrates. state 4 is after addition of oligomycin to inhibit the ATP synthase and thus corresponds to the maximum leak state where O2 consumption is limited by the buildup of the proton gradient and can only proceed as fast as the protons can leak back across the membrane. FCCP is added as an uncoupler, allowing free leakage of protons across the inner membrane, and thus measures maximum possible O2 flux. There are no defined normal ranges, but higher state 3 and uncoupled flux indicate better mitochondrial function, while state 4 is needed to correct state 3 to the fully coupled flux.
Time frame: End of each 6 week intervention period
Mito content by Western Blotting of electron transport chain complexes I, II, III, and V. complex 1 utilizes NADH from pyruvate/malate/glutamate while complex II utilizes FADH from succinate. complex III is the cytochrome c reductase while complex V is the ATP synthase.
Time frame: End of each 6 week intervention period
hsCRP (mg/L) by Beckman Coulter assay
Time frame: End of each 6 week intervention period
measure of autonomic function: ratio of fastest to slowest heart rate during valsalva maneuver
Time frame: Last Week of each 6 Week Intervention Period (over 7 days)
Mean Glucose & Glucose Standard Deviation (Glycemic Variability) by Dexcom CGM
Time frame: Last Week of each 6 Week Intervention Period (over 7 days)
Percent of time less than 70 mg/dL during the final week of each phase by Dexcom CGM.
Time frame: End of each 6 week intervention period
Glucagon (pg/ml); baseline on AM of each phase final study visit.
Time frame: End of each 6 week intervention period
Glucose (mg/dL), triglycerides (mg/dL), cholesterol (mg/dL) at baseline after each phase
Time frame: End of each 6 week intervention period
fatty acids (microeq/L) at baseline after each phase in the AM of the final visit
Time frame: End of each 6 week intervention period
glycerol (micromol/L) at baseline after each phase in the AM of the final phase visit
Time frame: End of each 6 week intervention period
insulin (microIU/ml) at baseline after each phase in the AM of the final phase visit
Time frame: End of each 6 week intervention period
lactate (mmol/L) at baseline after each phase in the AM of the final phase visit
Time frame: End of each 6 week intervention period
adiponection (microg/ml) at baseline after each phase in the AM of the final phase visit
Time frame: End of each 6 week intervention period
endothelin-1 at baseline after each phase in the AM of the final phase visit by peninsula labs radioimmunoassay
Time frame: End of each 6 week intervention period
Measured by 31P-mass spec. This ratio measures mitochondrial efficiency. The higher the ratio, the more efficiently the individual converts metabolic substrates into ATP, with the ATP then available for energy-demanding cellular processes such as protein synthesis and biomass production
Time frame: End of each 6 week intervention period
Measured by 31P-mass spec. ADP time constant and phosphocreatine time constant. ADP time constant is a measure of the time required to convert ADP → ATP and is a measure of muscle mitochondrial health (energy metabolism). A faster recovery is a better outcome; a slower recovery is a worse outcome. Similarly for phosphocreatine.
Time frame: End of each 6 week intervention period
Measured by 31P-mass spec. For each measure, a higher value indicates better mitochondrial function. All re calculated from multiple measures from the MRS spectra. These are relatively new research measures and normal values are not known or generally accepted.
Time frame: End of each 6 week intervention period
Measured by 31P-mass spec. A higher value indicates better mitochondrial function. All re calculated from multiple measures from the MRS spectra. These are relatively new research measures and normal values are not known or generally accepted. Oxidative Phosphorylation measures the rate at which electron transport activity generates phosphorylated energy sources (ATP and PCr)
Time frame: End of each 6 week intervention period
Measured by 31P-mass spec. Anaerobic glycolysis measures the amount of anaerobic ATP generation for energy. It is generally felt that a higher value here reflects impaired mitochondrial function necessitating greater reliance on anaerobic metabolism.
Time frame: End of each 6 week intervention period
Cardiac output
Time frame: End of each 6 week intervention period
PAI-1 exploratory thromobotic marker.
Time frame: End of each 6 week intervention period
ICAM
Time frame: End of each 6 week intervention period
TBARs, GSSG:GSH ratio
Time frame: End of each 6 week intervention period
oxidant generation
Time frame: End of each 6 week intervention period
IL6, TNF alpha
Time frame: after each 6 week intervention
exploratory measure looking at H2O2 production. not performed due to equipment not available.
University of Colorado, Denver
Other
Acronym: MeT1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05243628
Autoimmune Diseases, Diabetes Mellitus
Loma Linda, California, United States
View Trial DetailsNCT02693938
Autoimmune Diseases, Diabetes Mellitus
New Haven, Connecticut, United States
View Trial DetailsNCT01816165
Autoimmune Diseases, Diabetes Mellitus
Aurora, Colorado, United States
View Trial DetailsNCT04157738
Autoimmune Diseases, Diabetes Mellitus
Atlanta, Georgia, United States
View Trial Details